Papillary Thyroid Cancer - Pipeline Review, H2 2016


#862896

72pages

Global Markets Direct

$ 2000

In Stock

Papillary Thyroid Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Papillary Thyroid Cancer Pipeline Review, H2 2016, provides an overview of the Papillary Thyroid Cancer (Oncology) pipeline landscape.

Papillary thyroid cancer, also known as papillary thyroid carcinoma, is the most common form of thyroid cancer. Symptoms include throat pain, difficulty swallowing or breathing and hoarse voice. Risk factors for papillary thyroid cancer include radiation exposure and a family history of thyroid cancer. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Papillary Thyroid Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Papillary Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively for Papillary Thyroid Cancer.

Papillary Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Papillary Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Papillary Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Papillary Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Papillary Thyroid Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Papillary Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Papillary Thyroid Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Papillary Thyroid Cancer - Overview 7
Papillary Thyroid Cancer - Therapeutics under Development by Companies 8
Papillary Thyroid Cancer - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Papillary Thyroid Cancer - Products under Development by Companies 12
Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 13
Blueprint Medicines Corporation 13
Daiichi Sankyo Company, Limited 14
Ignyta, Inc. 15
Novartis AG 16
Pfizer Inc. 17
Synactix Pharmaceuticals, Inc. 18
Vaccinex, Inc. 19
Papillary Thyroid Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BLU-667 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
dabrafenib mesylate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
entrectinib - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
everolimus - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
pasireotide - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
PLX-7486 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
PLX-8394 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
RXDX-105 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
sunitinib malate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SYN-001 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
VX-15 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Papillary Thyroid Cancer - Dormant Projects 69
Papillary Thyroid Cancer - Discontinued Products 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Papillary Thyroid Cancer, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Papillary Thyroid Cancer - Pipeline by Blueprint Medicines Corporation, H2 2016 13
Papillary Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 14
Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H2 2016 15
Papillary Thyroid Cancer - Pipeline by Novartis AG, H2 2016 16
Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016 17
Papillary Thyroid Cancer - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016 18
Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Papillary Thyroid Cancer - Dormant Projects, H2 2016 69
Papillary Thyroid Cancer - Discontinued Products, H2 2016 70

List of Figures
Number of Products under Development for Papillary Thyroid Cancer, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Top 10 Targets, H2 2016 21
Number of Products by Stage and Top 10 Targets, H2 2016 21
Number of Products by Top 10 Mechanism of Actions, H2 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28